University of Minnesota

John R Ohlfest

Michael R Olin

Daniel A Vallera

Walter C Low

Jayanth Panyam

David M Ferguson

Courtney Aldrich

Suresh Kumar Swaminathan

Wenshou Wang

Chun Wang

This disclosure describes polypeptides fragments of annexin II, variants thereof, compositions that includes such fragments and/or variants, and methods of using such frag and/or variants.

Annexin II variant compositions and methods

The invention provides semi-solid systems for delivering biologically active materials that include a polymer comprising 1) one or more units of formula Ia, IIa, or IIIa: (formula Ia, IIa, IIIa) and 2) one or more units comprising polycaprolactone; wherein R and Rhave any of the values defined in the application.

Semi-solid delivery systems

The present invention provides compositions and methods that involve the 36 kDa annexin II monomer, which has been identified as having immunostimulatory properties. Accordingly, in one aspect, the invention provides compositions that include at least one 36 kDa annexin II monomer or an immunomodulatory fragment thereof. In another aspect, the invention provides methods that include administering to a subject a composition that includes at least one 36 kDa annexin II monomer or an immunomodulatory fragment thereof. In another aspect, the invention provides methods that induce an in situ increase in the 36 kDa annexin II monomer by administering to a subject an amount of composition effective to induce localized hypoxia sufficient to cause a localized increase in annexin II.

Annexin II compositions

The invention provides compounds of formula I: wherein R-R, R, and Rhave any of the values defined herein, and salts thereof. The compounds have immunomodulatory properties.

Immunomodulators and immunomodulator conjugates

The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).

Therapeutic composition for treatment of glioblastoma

Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Single-chain variable fragment anti-CD133 antibodies and uses thereof

Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Single chain variable fragment anti-CD133 antibodies and uses thereof

The invention provides compounds of formula I: wherein R1-R3, Ra, and Rb have any of the values defined herein, and salts thereof. The compounds have immunomodulatory properties. 

Growing community of inventors

Minneapolis, MN, United States of America

John R Ohlfest